OXNARD, Calif., Oct. 10, 2018 — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, will be presenting at this year’s CannX Conference on October 15 at 11:15 AM in Tel Aviv, Israel. CURE Pharmaceutical CEO Rob Davidson will present on “Maximizing and Understanding the Benefits of Proprietary Delivery Technologies for Increasing Bioavailability of Cannabinoid Molecules” and will be meeting with investors.
“With over 140 cannabinoid molecules present in the cannabis plant, we have only seen a glimpse of the potential of cannabinoids to treat many diseases and illnesses,” said Davidson. “CURE is focused on developing the most efficient delivery systems, such as CUREfilm™, to improve the absorption of the molecules for optimal effect on the endocannabinoid system.”
Davidson will be highlighting the vast amount of research on cannabinoids and their therapeutic potential in many indications. These potentially therapeutic molecules have low bioavailability and GI absorption thus requiring novel delivery methods. He also will discuss the different encapsulation technologies that deliver cannabinoid molecules for better absorption and bioavailability, such as CUREfilm.
CannX was created as an interactive forum for top global leaders in all areas of medical cannabis to explore the latest scientific and clinical research, agricultural practices and innovation and business opportunities in medical cannabis.
The CannX International Medical Cannabis Conference will take place in Tel Aviv at the Tel Aviv Convention Center, Pavilion 2 on October 14 – 16. Those interested can find more information at https://cannx.org/2018.
If you would like to schedule a meeting with CURE Pharmaceutical, please contact Ashley Ray at [email protected]
About CURE Pharmaceutical CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
CURE Pharmaceutical Media Contact: Ashley Ray Olmstead Williams Communications [email protected] 310-824-9000